Related Experiment Video

Updated: May 13, 2026

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
12:04

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy

Published on: August 14, 2012

Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches

Kjell Oberg1, Oriol Casanovas, Justo P Castaño

  • 1Department of Endocrine Oncology, University Hospital, Uppsala, Sweden. kjell.oberg@medsci.uu.se

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 6, 2013
PubMed

Insights

Recent advances in neuroendocrine tumor (NET) treatment include somatostatin analogues for symptom control and tumor growth, alongside targeted therapies like sunitinib and everolimus for advanced pancreatic NETs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The understanding and treatment of neuroendocrine tumors (NETs) have evolved significantly.
  • Somatostatin analogues demonstrate efficacy in managing hormone hypersecretion and slowing tumor growth in advanced carcinoid.
  • Targeted therapies, including VEGF and mTOR inhibitors, show promise for advanced pancreatic NETs.

Purpose of the Study:

  • To review recent advancements in NET treatment strategies.
  • To explore the role of molecular characterization in predicting treatment response and overcoming drug resistance.
  • To highlight emerging research into epigenetic modifications in NET growth.

Main Methods:

  • Review of recent clinical trials and genomic studies on neuroendocrine tumors.
  • Analysis of data on somatostatin analogues, sunitinib, and everolimus efficacy.
  • Examination of research into chromatin remodeling and epigenetic pathways in NETs.

Main Results:

  • Somatostatin analogues can control symptoms and slow tumor growth in advanced carcinoid.
  • Sunitinib and everolimus are effective in patients with advanced pancreatic NETs.
  • Genomic studies suggest chromatin remodeling and epigenetic modifications are key in NET growth.

Conclusions:

  • Molecular characterization of NETs is crucial for personalized treatment selection and overcoming resistance.
  • Targeted therapies and understanding epigenetic pathways offer new therapeutic and diagnostic potential for NET patients.

More Related Videos

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...